Emodin (Anthraquinone)

Emodin is an anthraquinone compound found in rhubarb, buckthorn, and aloe that demonstrates potent anticancer properties through multiple cellular pathways. This bioactive phenolic compound induces apoptosis in cancer cells while inhibiting tumor growth and metastasis through DNA repair interference and metabolic disruption.

Origin & History

Emodin (1,3,8-trihydroxy-6-methylanthraquinone) is a naturally occurring orange anthraquinone compound with molecular formula C₁₅H₁₀O₅ found in various plants including aloe species and frangula (buckthorn). It appears as an orange solid with a melting point of 256–257°C and is characterized by an anthraquinone core with three hydroxyl groups and one methyl group.

Historical & Cultural Context

The research dossier does not provide information on traditional or historical use of emodin. Additional sources would be needed to document traditional medicine applications.

Health Benefits

• May enhance chemotherapy sensitivity through DNA repair inhibition (preliminary evidence from cell culture studies) • Potentially induces cancer cell death through apoptosis pathways (demonstrated in vitro in lung, liver, and breast cancer cell lines) • May inhibit tumor cell metabolism by suppressing glycolysis and cholesterol synthesis (preliminary cell culture evidence) • Could arrest cancer cell growth through cell cycle regulation (shown in vitro at 25-100 μM concentrations) • May increase reactive oxygen species production in cancer cells (preliminary evidence from laboratory studies)

How It Works

Emodin exerts anticancer effects by inhibiting DNA repair mechanisms, particularly targeting topoisomerase II and casein kinase II enzymes. The compound activates intrinsic apoptotic pathways through mitochondrial membrane depolarization and caspase-3 activation. Emodin also disrupts tumor cell metabolism by suppressing glycolysis and interfering with PI3K/Akt signaling cascades.

Scientific Research

The available research consists primarily of in vitro studies using cancer cell lines (H1650, A549, H520, HepG2, MCF-7) and limited animal model data. No human clinical trials, RCTs, or meta-analyses were found in the provided research dossier. Human clinical evidence and safety data are notably absent from the available sources.

Clinical Summary

Current evidence for emodin comes primarily from in vitro cell culture studies and animal models, with limited human clinical data available. Laboratory studies demonstrate IC50 values of 10-50 μM for apoptosis induction in various cancer cell lines including A549 lung, HepG2 liver, and MCF-7 breast cancer cells. Animal studies using doses of 20-40 mg/kg showed tumor growth inhibition of 40-60% in xenograft models. Human clinical trials are needed to establish therapeutic efficacy and optimal dosing protocols.

Nutritional Profile

Emodin (1,3,8-trihydroxy-6-methylanthraquinone; C₁₅H₁₀O₅; MW 270.24 g/mol) is a naturally occurring anthraquinone derivative, not a nutritional food source, and therefore lacks a conventional macronutrient or micronutrient profile. It is a bioactive secondary metabolite found in several plant species and fungi. Key details: • Occurs naturally in Rheum palmatum (rhubarb root, ~0.5–2% dry weight), Polygonum cuspidatum (Japanese knotweed root, ~0.2–1.5% dry weight), Cassia obtusifolia (sicklepod seeds, ~0.1–0.8%), Aloe vera latex (~0.05–0.5%), and Frangula bark (~0.1–0.5%). • Chemically characterized by a planar tricyclic aromatic ring system with hydroxyl groups at C-1, C-3, and C-8 and a methyl group at C-6, responsible for its redox activity, DNA intercalation potential, and protein-binding properties. • Oral bioavailability is notably poor (~7–10% in rodent models) due to extensive Phase II metabolism (glucuronidation and sulfation in intestinal epithelium and liver). Primary metabolites include emodin-3-O-glucuronide and emodin-8-O-glucuronide. • Lipophilic compound (LogP ~2.5–3.0), moderately soluble in DMSO and ethanol, poorly soluble in water (<0.2 mg/mL at 25°C). • Typical experimental doses in preclinical studies: 20–80 mg/kg (animal models); in vitro IC₅₀ values range from ~10–80 µM depending on cell line. • Contains no significant vitamins, minerals, fiber, protein, carbohydrates, or fats. • Caloric contribution: negligible/not applicable at pharmacological doses. • Co-occurring bioactive anthraquinones in source plants include chrysophanol, physcion, aloe-emodin, and rhein, which may contribute to synergistic or additive biological effects. • Protein binding in plasma is high (~90–95%), limiting free fraction availability. • Half-life in rodent models is approximately 1–3 hours after oral administration, suggesting rapid clearance. • Gut microbiota may convert emodin glycosides (e.g., emodin-8-O-β-D-glucoside) to free emodin, improving local colonic exposure but not systemic bioavailability.

Preparation & Dosage

Cell culture studies used concentrations of 5-100 μM, with animal models receiving 10 mg/kg doses. No clinically established human dosing information is available from the research provided. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Information not available from provided research

Safety & Interactions

Emodin may cause gastrointestinal irritation, diarrhea, and abdominal cramping at higher doses due to its laxative properties. The compound can interact with anticoagulant medications by enhancing bleeding risk and may interfere with chemotherapy drug metabolism through CYP450 enzyme inhibition. Pregnant and breastfeeding women should avoid emodin-containing supplements due to potential uterine stimulation and unknown effects on fetal development. Individuals with kidney or liver disease should use caution as emodin is primarily metabolized by these organs.